To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Did you know that a component of your blood could be used ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Intravenous immunoglobulin (IVIG) therapy involves infusing patients with naturally occurring IgG antibodies to treat autoimmune conditions. With origins dating back to the 1950s, IVIG is currently ...

Preterm newborns are susceptible of invasion by microorganisms due to immaturity of their immune system. This study aimed at assessing the effect of IV immunoglobulins as supportive treatment in ...

ARLINGTON, Texas--(BUSINESS WIRE)--AOM Infusion (“AOM”), a leading provider of specialty infusion and pharmacy services for chronic and complex conditions, has been selected by Kedrion Biopharma as a ...

"[O]ur study, which has the largest cohort to date, did not show an increased rate of VTEs in patients with DM on IVIG. Therefore, it is safe to start patients on this medicine as it is one of our ...

AOM Infusion ("AOM"), a leading specialty infusion pharmacy and provider, today announced it has joined Kedrion Biopharma’s limited distribution network for QIVIGY®, a new 10% immune globulin (Ig) ...

− GAMMAGARD LIQUID ERC [immune globulin infusion (human)] with Less Than or Equal to 2 µg/mL IgA in a 10% Solution is Now Available by Prescription for Intravenous or Subcutaneous Use in People Aged ...

CIC were studied by Raji cell assay in 23 patients with AIDS and ARC before and after IVIG. All patients had elevated CIC prior to initiative IVIG treatment. Patients were followed for an average of ...

The prescribed dosage for Hizentra (immune globulin subcutaneous [human]) may vary depending on an individual’s treatment plan. Other factors, including your specific diagnosis, body weight, and ...

“The approval of GAMMAGARD LIQUID ERC reinforces our commitment to supporting individualized treatment approaches for people with primary immunodeficiency, including a therapeutic option that has the ...